

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

# Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	mation		
Given Name (First Name)  Jürgen	2. Surname (Last Name) Behr	V 7	3. Date 19-July-2017
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's N Christopher J Ryerson	Name
5. Manuscript Title A Standardized Diagnostic Ontology fo	or Fibrotic Interstitial Lung	Disease: An International	Working Group Perspective
6. Manuscript Identifying Number (if you k Blue-201702-0400PP.R1	know it)		
Section 2. The West Hadron	Consideration for Publi		
Did you or your institution <b>at any time</b> recany aspect of the submitted work (includin statistical analysis, etc.)?  Are there any relevant conflicts of interesting the state of the stat	ng but not limited to grants, da		
Section 3. Relevant financia	l activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as desc clicking the "Add +" box. You should re Are there any relevant conflicts of inte	ribed in the instructions. U eport relationships that we	se one line for each entity	y; add as many lines as you need by
If yes, please fill out the appropriate in	formation below.		
Name of Entity	Grant	n-Financial Other? C	Comments
Bayer			
Boehringer-Ingelheim	<b>V V</b>		
Actelion			
Roche	<b>V V</b>		



Section 4. Intellectual Property 2.4
Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
JB is member of national and international IPF guideline committees.  At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
JB is member of national and international IPF guideline committees. Outside the presented work he receives honoraria from Actelion, Bayer, Boehringer-Ingelheim and Roche and grants from Boehringer-Ingelheim and Roche.

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform				
Identifying Information	ation			
1. Given Name (First Name) Harold	2. Surname (Last Name) Collard		3. Date 16-May-2017	
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's	s Name	
5. Manuscript Title A Standardized Diagnostic Ontology for	Fibrotic Interstitial Lung I	Disease: An Internation	al Working Group Perspective	
6. Manuscript Identifying Number (if you kno Blue-201702-0400PP.R1	ow it)			
Section 2. The Work Under Co	nsideration for Public	ation		
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest	but not limited to grants, da	. , ,	•	
Section 3. Relevant financial a	activities outside the s	submitted work.		
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interest lf yes, please fill out the appropriate information.	n the table to indicate who bed in the instructions. Us ort relationships that wer st?	ether you have financia se one line for each enti	ty; add as many lines as you n	eed by
Name of Entity	Grant? Personal Nor	n-Financial other?	Comments	
aTyr Pharmaceuticals				
Bayer				
Boehringer Ingelheim				
Bristol-Myers Squibb				
Global Blood Therapeutics				
Genoa				
lmmuneWorks				
Moerae Matrix				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Navitor		<b>✓</b>				
Parexel		<b>✓</b>				
Patara		<b>✓</b>				
PharmAkea		<b>√</b>				
Prometic		$\checkmark$				
Takeda		$\checkmark$				
Toray		<b>✓</b>				
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No  Section 5. Relationships not severed above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest  At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						

Dr. Collard reports personal fees from Alkermes, personal fees from aTyr Pharmaceuticals, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from Global Blood Therapeutics, personal fees from Genoa, personal fees from ImmuneWorks, personal fees from Moerae Matrix, personal fees from Navitor, personal fees from Parexel, personal fees from Patara, personal fees from Pharma Capital Partners, personal fees from PharmAkea, personal fees from Prometic, personal fees from Takeda, personal fees from Toray, personal fees from Xfibra, outside the submitted work;



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	nation							
1. Given Name (First Name) Tamera	2. Surname (Last N Corte	lame)	3. Date 19-July-2017					
4. Are you the corresponding author?	☐ Yes ✓ No		ding Author's Name er J Ryerson					
5. Manuscript Title A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective								
6. Manuscript Identifying Number (if you k Blue-201702-0400PP.R1	now it)							
Section 2. The Work Under C		<b>D</b> 111 d						
The Work Under C	onsideration for	Publication						
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to g							
Section 3. Relevant financial	activities outsid	e the submitted	work.					
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re Are there any relevant conflicts of inter If yes, please fill out the appropriate inf	ibed in the instruct port relationships test?	ions. Use one line f	or each entity; add as many lines as	you need by				
Name of Entity	Grant? Person	Non-Financial Support?	Other? Comments					
Boehringer Ingleheim	<b>V</b>	<b>V</b>	Unrestricted educational gra and speaker fees, advisory b payment.					
Roche	<b>/</b>		Unrestricted educational gra and speaker fees, advisory b payment.					
Bayer		П	Unrestricted educational gra	ant				
Actelion			Unrestricted educational gra	ant				
BMS			Unrestricted educational gra	ant				



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments	
Sanofi	<b>✓</b>				Unrestricted educational grant	
Astra Zeneca		<b>✓</b>			Advisory Board payment	
Section 4. Intellectual Dranget						
Intellectual Propert	y Patei	nts & Co <sub>l</sub>	pyrights			
Do you have any patents, whether planno	ed, pendir	ng or issue	ed, broadly releva	nt to the	work? Yes 🗸 No	
Section 5. Relationships not co	overed a	bove				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest  At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.						nents.
Section 6. Disclosure Statemen	nt					
Based on the above disclosures, this form below.	ı will autoı	matically (	generate a disclos	sure state	ment, which will appear in the box	
Dr. Corte reports grants, personal fees as Roche, grants from Bayer, grants from Acoutside the submitted work; .						om



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation								
Given Name (First Name)  Vincent	2. Surnar Cottin	me (Last Nar	ne)		3. Date 27-July-2017				
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspond Christoph	_					
5. Manuscript Title A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective									
6. Manuscript Identifying Number (if you kno Blue-201702-0400PP.R1	ow it)								
Section 2. The Work Under Co									
The Work Under Co	nsidera	tion for P	ublication						
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest	but not lim		its, data monitoring			c.) for			
Section 3. Polovant financial a			de e colone totale						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest?    Yes    No  If yes, please fill out the appropriate information below.									
Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments				
Actelion		<b>✓</b>			Consultancy Lecture fees Travel to medical meetings				
Boehringer Ingelheim		<b>✓</b>			Development of educational presentations Consultancy Lecture fees Travel to medical meetings				
Bayer		<b>✓</b>			Consultancy				
Biogen Idec		<b>√</b>			Consultancy				
Gilead		<b>✓</b>			Member of adjudication committee				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
GSK		<b>✓</b>			Consultancy Travel to medical meetings	
MSD		<b>✓</b>			Consultancy	
Novartis		<b>✓</b>			Consultancy Lecture fees Travel to medical meetings	
Roche		<b>✓</b>			Consultancy Lecture fees Travel to medical meetings	
Sanofi		<b>✓</b>			Consultancy Lecture fees	
Boehringer Ingelheim	<b>✓</b>				Grant to foundation Lyon1	
GSK	<b>✓</b>				Grant to foundation Lyon1	
Actelion	<b>✓</b>				Grant to foundation Lyon1	
Roche	<b>✓</b>				Grant to foundation Lyon1	
Promedior		<b>✓</b>			Chair of DSMB	
Cellgene		$\checkmark$			DSMB	
Section 4. Intellectual Property Patents & Copyrights						
Do you have any patents, whether plann	Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo					
Section 5. Relationships not c	overed	above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						



#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Cottin reports personal fees from Actelion, personal fees from Boehringer Ingelheim, personal fees from Bayer, personal fees from Biogen Idec, personal fees from GSK, personal fees from MSD, personal fees from Novartis, personal fees from Roche, personal fees from Sanofi, grants from Boehringer Ingelheim, grants from GSK, grants from Actelion, grants from Roche, personal fees from Promedior, personal fees from Cellgene, outside the submitted work; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Danoff 1



Section 1.	Identifying Inform	nation				
1. Given Name (Fi Sonye	rst Name)	Surname (Last Name)     Danoff	3. Date 19-July-2017			
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Christopher J Ryerson			
5. Manuscript Title A Standardized I		r Fibrotic Interstitial Lung	Disease: An International Working Group Perspective			
6. Manuscript Ide Blue-201702-040	ntifying Number (if you kr 00PP.R1	now it)	_			
	ı					
Section 2.	The Work Under C	onsideration for Public	cation			
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,			
Section 3.	Relevant financial	activities outside the	submitted work			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Yes No						
Section 4.	Intellectual Prope	rty Patents & Copyrig	ghts			
Do you have any			oadly relevant to the work? Yes V No			

Danoff 2



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Danoff has nothing to disclose.

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Danoff 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	-4:							
Identifying Information	ation							
1. Given Name (First Name) Kevin	2. Surname Flaherty	e (Last Nam	e)		3. Date 19-July-2017			
4. Are you the corresponding author?	Yes	<b>√</b> No	Correspond	-				
Christopher J Ryerson  5. Manuscript Title A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective								
6. Manuscript Identifying Number (if you kno Blue-201702-0400PP.R1	ow it)							
Section 2								
Section 2. The Work Under Co	nsideratio	on for Pu	ıblication					
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest	but not limit	ed to grant	s, data monitoring			etc.) for		
Section 3. Relevant financial a	ctivities c	outside t	he submitted	work.				
Place a check in the appropriate boxes ir of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interest fill out the appropriate info	oed in the ir ort relation st?	nstruction ships that s	s. Use one line fo	r each en	tity; add as many lines as you ne	ed by		
Name of Entity	Grant	ersonal Fees?	Non-Financial Support?	Other?	Comments			
Boehringer Ingelheim	<b>✓</b>	<b>√</b>						
Roche/Genentech	<b>✓</b>	<b>✓</b>						
ImmuneWorks		<b>✓</b>						
Veracyte		<b>✓</b>						
Biogen		<b>✓</b>						
Afferent		<b>✓</b>						
Aeolus		<b>✓</b>						
Pharmakea		<b>✓</b>						



Name of Entity	Grant? Personal Fees?	Non-Financial Support? Other	Comments
Fibrogen			
Sanofi-Genzyme			
Section 4			
Section 4. Intellectual	Property Patents & Cop	yrights	
Do you have any patents, whet	ner planned, pending or issue	d, broadly relevant to the	work? Yes No
Section 5. Relationshi	ips not covered above		
potentially influencing, what your potentially influencing, what you had you	ou wrote in the submitted wor nips/conditions/circumstances ditions/circumstances that pre otance, journals will ask autho	k? s are present (explain belowsent a potential conflict of the confirm and, if neces	f interest sary, update their disclosure statements
Section 6. Disclosure 9	Statement		
Based on the above disclosures below.	, this form will automatically g	generate a disclosure state	ement, which will appear in the box
personal fees from ImmuneWo	rks, personal fees from Veracy	rte, personal fees from Bio	ersonal fees from Roche/Genentech, gen, personal fees from Afferent, n, personal fees from Sanofi-Genzyme,



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inforn	nation								
1. Given Name (Fi David	1. Given Name (First Name)  David  2. Surname (Last Name)  Lederer				3. Date 24-July-2017					
4. Are you the co	responding author?	Yes	✓ No	•	Corresponding Author's Name Christopher Ryerson					
5. Manuscript Titl A Standardized		or Fibrotic I	nterstitial L	ung Disease: An I	Internatio	onal Working Group Perspective				
6. Manuscript Ide	ntifying Number (if you kı	now it)								
Section 2.	The Work Under C	onsidera	tion for P	ublication						
any aspect of the	submitted work (including					ent, commercial, private foundation, e cudy design, manuscript preparation,	tc.) for			
statistical analysis, Are there any re	levant conflicts of inter	est?	Yes ✓	No						
Section 3.										
Section 3.	Relevant financial	activities	outside '	the submitted	work.					
of compensation	n) with entities as descr	ibed in the	instruction	ns. Use one line fo	or each ei	cial relationships (regardless of am ntity; add as many lines as you nee e <b>36 months prior to publication</b>	d by			
•	levant conflicts of inter	·	. —	No						
If yes, please fill	out the appropriate inf	ormation b	elow.							
Name of Entity		Grant?	Personal Fees	Non-Financial Support?	Other?	Comments				
Genentech/Roche			<b>✓</b>			Consulting/Advisory Board				
Boehringer-Ingelhei	n	<b>√</b>	<b>✓</b>			institutional support for clinical trial and advisory board				
/eracyte			<b>✓</b>			consulting/advisory board for ILD				
Degge Group			<b>✓</b>			Adjudication committee				
France Foundation			<b>✓</b>			Steering committee, lecture fees, generation of education content				
ibrogen		<b>✓</b>	<b>✓</b>			institutional support for clinical trial; consulting				



	7	Personal	Non-Financial	7	
Name of Entity	Grant?	Fees?	Support?	Other	Comments
Global Blood Therapeutics	<b>✓</b>	<b>√</b>			institutional support for clinical trial; consulting
Patara		<b>✓</b>			consulting on IPF
Philips Respironics		<b>✓</b>			consulting on IPF
Pulmonary Fibrosis Foundation				<b>✓</b>	Columbia University receives fees for consulting services
Immuneworks		<b>✓</b>			consulting on IPF
Sanofi Genzyme		<b>✓</b>			consulting on IPF
Section 4. Intellectual Proper	ty Pate	ents & Cop	pyrights		
Do you have any patents, whether planr	ned, pend	ing or issue	ed, broadly releva	nt to the	work? ☐ Yes ✓ No
Section 5. Relationships not o	rovered	ahove			
Are there other relationships or activities potentially influencing, what you wrote  Yes, the following relationships/cond	in the sub	omitted wo	rk? es are present (exp	olain belo	ow):
No other relationships/conditions/ci	rcumstan	ces that pre	esent a potential	conflict o	finterest
On occasion, journals may ask authors to					sary, update their disclosure statements. elationships.
Section 6. Disclosure Stateme	ent				
Based on the above disclosures, this forr below.	n will auto	omatically (	generate a disclo	sure state	ment, which will appear in the box
Dr. Lederer reports personal fees from G fees from Veracyte, personal fees from E Fibrogen, grants and personal fees from Respironics, other from Pulmonary Fibro Genzyme, outside the submitted work;	Degge Gro Global B Osis Found	oup, persor lood Thera	nal fees from Fran peutics, personal	ce Found fees from	lation, grants and personal fees from n Patara, personal fees from Philips



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Lee 1



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Joyce	2. Surname (Last Name) Lee	3. Date 19-July-2017
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Christopher J Ryerson
5. Manuscript Title A Standardized Diagnostic Ontology for	r Fibrotic Interstitial Lung	Disease: An International Working Group Perspective
6. Manuscript Identifying Number (if you kn Blue-201702-0400PP.R1	ow it)	_
Section 2. The Work Under Co	onsideration for Public	
Did you or your institution <b>at any time</b> recei	ve payment or services from but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Us port relationships that wer est?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.
Name of Entity	Grant? Personal Fees? S	ort? Other? Comments
Parexel		Consultant
ntermune		Steering Committee
Genentech		Advisory Board
Section 4. Intellectual Proper	ty Patents & Copyric	hts
Do you have any patents, whether plant	ned, pending or issued, br	oadly relevant to the work? Yes V No

Lee 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Lee reports personal fees from Parexel, personal fees from Intermune, personal fees from Genentech, outside the submitted work; .

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Lee 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been sound to an ent

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Lynch 1



Section 1. Identifying Inform	mation		
1. Given Name (First Name) David	2. Surname (Last Name) Lynch	3. Date 28-July-2017	
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Christopher J Ryerson	
5. Manuscript Title A Standardized Diagnostic Ontology fo	or Fibrotic Interstitial Lung	Disease: An International Working Group	Perspective
6. Manuscript Identifying Number (if you k Blue-201702-0400PP.R1	now it)		
		_	
Section 2. The Work Under C	Consideration for Publ	cation	
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, d	n a third party (government, commercial, privat ata monitoring board, study design, manuscrip	
Section 3. Relevant financial	l activities outside the	submitted work.	
of compensation) with entities as desc	ribed in the instructions. Leport relationships that we rest?	nether you have financial relationships (reg lse one line for each entity; add as many lir ere <b>present during the 36 months prior t</b> o	nes as you need by
Name of Entity	Grant? Personal No	on-Financial Other? Comments	
NHLBI	<b>/</b>		
Parexel		Research Support	
Veracyte		Research Support	
Boehringer Ingelheim			
Genentech/Roche			

Lynch 2



Section 4. In	tellectual Property Patents & Copyrights
Do you have any pa	tents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5.	elationships not covered above
	cionships or activities that readers could perceive to have influenced, or that give the appearance of ng, what you wrote in the submitted work?
Yes, the followin	g relationships/conditions/circumstances are present (explain below):
✓ No other relation	nships/conditions/circumstances that present a potential conflict of interest
On occasion, journa	script acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Is may ask authors to disclose further information about reported relationships.
Section 6.	isclosure Statement
Based on the above below.	disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	rants from NHLBI, personal fees from Parexel, other from Veracyte, personal fees from Boehringer I fees from Genentech/Roche, outside the submitted work; .

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Lynch 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation					
1. Given Name (First Name) Fernando	2. Surname (Last Nam Martinez	ne)	3. Date 01-August-2017			
4. Are you the corresponding author?	Yes ✓ No		Corresponding Author's Name Christopher J Ryerson			
5. Manuscript Title A Standardized Diagnostic Ontology for	r Fibrotic Interstitial Lu	ung Disease: An I	nternational Working Group Perspecti	ve		
6. Manuscript Identifying Number (if you kn Blue-201702-0400PP.R1	ow it)					
Section 2. The Work Under Co	onsideration for Pu	ıblication				
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grant					
Section 3. Relevant financial	activities outside t	he submitted	work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest?  Yes  No  If yes, please fill out the appropriate information below.						
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments			
Bayer			IPF Study Steering Committee			
Boehringer Ingelheim		<b>✓</b>	IPF Study Steering Committee; II Advisory Board	PF		
Centocor		<b>✓</b>	✓ IPF Study Steering Committee			
Gilead Sciences		<b>✓</b>	IPF Study Steering Committee			
Genentech			IPF Advisory Board			
Bellerophon (formerly Ikaria)			IPF Advisory Board			
Kadmon			IPF Advisory Board			



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Nycomed/Takeda		<b>✓</b>			IPF Advisory Board
Pfizer		$\checkmark$			IPF Advisory Board
American Thoracic Society		$\checkmark$			IPF CME programs
Academic CME		<b>✓</b>			IPF CME program
MedEd Consulting		$\checkmark$			IPF CME program
National Association for Continuing Education		$\checkmark$			IPF CME programs
Axon Communication		$\checkmark$			IPF teleconference consultation
Johnson & Johnson		$\checkmark$			IPF teleconference consultation
Biogen/Stromedix			<b>✓</b>		IPF Study DSMB
National Institutes of Health	<b>✓</b>				COPD and IPF studies
Clarion Communications		$\checkmark$			IPF Teleconference
Potomac Center for Medical Education (PCME)		<b>✓</b>			IPF CME programs
Merck (formerly Afferent)		<b>✓</b>			IPF Steering Committee
Adept Field Solutions (London, UK)		<b>✓</b>			IPF Teleconference
Patara		<b>✓</b>			IPF Study SC
Nitto					IPF Study Consultation
Veracyte				<b>✓</b>	IPF Diagnostic Study

	1		
Section 4.	Intellectual Property Patents & Copyrights		
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work?	✓ No	



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	ving relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Dr. Martinez reports personal fees from Bayer, personal fees, non-financial support and other from Boehringer Ingelheim, non-financial support and other from Centocor, non-financial support from Gilead Sciences, personal fees from Genentech, personal fees from Bellerophon (formerly Ikaria), personal fees from Kadmon, personal fees from Nycomed/Takeda, personal fees from Pfizer, personal fees from American Thoracic Society, personal fees from Academic CME, personal fees from MedEd Consulting, personal fees from National Association for Continuing Education, personal fees from Axon Communication, personal fees from Johnson & Johnson, non-financial support from Biogen/Stromedix, grants from National Institutes of Health, personal fees from Clarion Communications, personal fees from Potomac Center for Medical Education (PCME), personal fees from Merck (formerly Afferent), personal fees from Adept Field Solutions (London, UK),

personal fees from Patara, from Nitto, other from Veracyte, outside the submitted work; .

#### **Evaluation and Feedback**

below.

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Myers 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Jeffrey	2. Surname (Last Name) Myers	3. Date 19-July-2017
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Christopher J Ryerson
5. Manuscript Title A Standardized Diagnostic Ontology fo	r Fibrotic Interstitial Lung	Disease: An International Working Group Perspective
6. Manuscript Identifying Number (if you kr Blue-201702-0400PP.R1	now it)	
Section 2. The Work Under Co	onsideration for Publi	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	ibed in the instructions. Us port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper		
Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No

Myers 2



Section 5.	
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Myers has no	othing to disclose.

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Myers 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation					
1. Given Name (First Name) Ganesh	2. Surnar Raghu	ne (Last Nar	me)		3. Date 19-July-2017	
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspond Christoph	_		
5. Manuscript Title A Standardized Diagnostic Ontology for	Fibrotic I	nterstitial L	ung Disease: An	Internatio	onal Working Group Perspective	
6. Manuscript Identifying Number (if you kn Blue-201702-0400PP.R1	ow it)					
Section 2. The Work Under Co	onsidera	tion for P	ublication			
Did you or your institution <b>at any time</b> receing any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere	but not lim		nts, data monitoring			tc.) for
Section 3. Relevant financial a	activities	outside	the submitted	work.		
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repart there any relevant conflicts of interesting the series of the series	bed in the port relation st? // `	instruction inships that	ns. Use one line fo	or each er	ntity; add as many lines as you need	d by
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Boerhinger-Ingelheim		<b>✓</b>		<b>✓</b>	consultant : IPF studies	
BMS				<b>✓</b>	consultant : IPF studies	Ī
Fibrogen				<b>✓</b>	consultant : IPF studies	1
Gilead				<b>✓</b>	consultant : IPF studies	
Promedior				<b>✓</b>	consultant : IPF studies	
Roche-Genentech				<b>✓</b>	consultant : IPF studies	
Parata		<b>✓</b>		<b>✓</b>	consultant : IPF studies	
Sanofi				<b>✓</b>	consultant : IPF studies	



Name of Entity	Grant? Person	al Non-Financial	Other?	Comments	
United therapeutics			<b>✓</b>	consultant : ILD and PF studies	
/eracyte			<b>✓</b>	consultant: IPF studies	
Section 4. Intellectual Propert	y Patents & C	opyrights			
Do you have any patents, whether plann	ed, pending or iss	ued, broadly releva	nt to the	work? ☐ Yes ✓ No	
Section 5. Relationships not c	overed above				
Are there other relationships or activities potentially influencing, what you wrote i		•	influence	d, or that give the appearance of	
Yes, the following relationships/conditions/cir					
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					ːs.
Section 6. Disclosure Stateme	nt				
Based on the above disclosures, this form below.	n will automaticall	y generate a disclo	sure state	ement, which will appear in the box	
Dr. Raghu reports personal fees and oth Gilead , other from Promedior , other fro other from United therapeutics, persona	m Roche-Genente	ech , personal fees a	and other	from Parata , other from Sanofi ,	



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation				
1. Given Name (Fii Luca	rst Name)	2. Surnar Richeldi	ne (Last Nar	ne)		3. Date 26-July-2017
4. Are you the cor	responding author?	Yes	<b>√</b> No	Correspond Christoph	_	
5. Manuscript Title A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective						
6. Manuscript Ider Blue-201702-040	ntifying Number (if you kn 10PP.R1	ow it)				
Section 2.	The Work Under Co	onsiderat	tion for P	ublication		
any aspect of the s statistical analysis,	ubmitted work (including	but not lim	nited to grar			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
Section 3.	Relevant financial	activities	outside	the submitted	work.	
of compensation clicking the "Add Are there any rele	) with entities as descri	bed in the port relations:	instruction inships that	ns. Use one line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
nterMune		<b>✓</b>	<b>√</b>			Member of advisory board
Medimmune			<b>✓</b>			Member of advisory board
Biogen			<b>✓</b>			Consulting activity
Sanofi-Aventis			<b>✓</b>			Consulting activity
Roche			<b>✓</b>			Member of advisory board
mmuneWorks			<b>✓</b>			Consulting activity
Shionogi			<b>✓</b>			Speaker fee
Boehringer Ingelheim	1		<b>✓</b>			Member of Steering Committee



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
Celgene			Consulting activity	у
Nitto			Consulting activity	у
Continue A				
Section 4. Intellectual Propert	y Patents & Cop	oyrights		
Do you have any patents, whether planne	ed, pending or issue	d, broadly releva	nt to the work? Yes	✓ No
Section 5. Relationships not c	overed above			
Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/cond  No other relationships/conditions/circ  At the time of manuscript acceptance, journals may ask authors to	n the submitted wor itions/circumstance cumstances that pre urnals will ask autho	rk? s are present (expessent a potential or ers to confirm and	olain below): conflict of interest I, if necessary, update thei	
Section 6. Disclosure Statemen	nt			
Based on the above disclosures, this form below.	n will automatically <u>c</u>	generate a disclos	sure statement, which will	appear in the box
Dr. Richeldi reports grants and personal personal fees from InterMune, personal f Aventis, personal fees from Roche, perso Shionogi, outside the submitted work.	ees from Medimmu	ne, personal fees	from Biogen-Idec, person	al fees from Sanofi-



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

.....



1. Given Name (First Name)	2. Surname (Last Name)	3. Date 19-July-2017
4. Are you the corresponding author?		rresponding Author's Name rristopher J Ryerson
5. Manuscript Title A Standardized Diagnostic Ontolog	y for Fibrotic Interstitial Lung Disea	ase: An International Working Group Perspective
6. Manuscript Identifying Number (if yo Blue-201702-0400PP.R1	u know it)	
Section 2. The Work Unde	r Consideration for Publication	on
any aspect of the submitted work (inclu statistical analysis, etc.)?	<u> </u>	onitoring board, study design, manuscript preparation,
any aspect of the submitted work (inclustatistical analysis, etc.)? Are there any relevant conflicts of in	ding but not limited to grants, data m	onitoring board, study design, manuscript preparation,
any aspect of the submitted work (inclustatistical analysis, etc.)?  Are there any relevant conflicts of in Relevant finance.  Place a check in the appropriate boy of compensation) with entities as defined as the submitted work (inclustration).	ial activities outside the subressible in the table to indicate whethe escribed in the instructions. Use on	onitoring board, study design, manuscript preparation,
Section 3.  Relevant finance  Place a check in the appropriate box of compensation) with entities as declicking the "Add +" box. You should	terest? Yes No  ial activities outside the subress in the table to indicate whether escribed in the instructions. Use on I report relationships that were presented in the instructions that were presented in the instruction	nitted work.  r you have financial relationships (regardless of amouse line for each entity; add as many lines as you need l
any aspect of the submitted work (inclustatistical analysis, etc.)?  Are there any relevant conflicts of in Relevant finance.  Place a check in the appropriate boof compensation) with entities as defined as the submitted work (inclustration).	ial activities outside the subress in the table to indicate whether escribed in the instructions. Use on I report relationships that were preferences:	nitted work.  r you have financial relationships (regardless of amouse line for each entity; add as many lines as you need l
Section 3.  Relevant finance  Place a check in the appropriate box of compensation) with entities as declicking the "Add +" box. You should Are there any relevant conflicts of in lif yes, please fill out the appropriate	terest? Yes No  ial activities outside the subress in the table to indicate whether escribed in the instructions. Use on a report relationships that were preferest? Yes No information below.  Grant? Personal Non-Fin	nitted work.  r you have financial relationships (regardless of amouse line for each entity; add as many lines as you need be sent during the 36 months prior to publication.
any aspect of the submitted work (inclustatistical analysis, etc.)?  Are there any relevant conflicts of in Relevant finance.  Place a check in the appropriate box of compensation) with entities as declicking the "Add +" box. You should Are there any relevant conflicts of in	terest? Yes No  ial activities outside the subress in the table to indicate whethe escribed in the instructions. Use on a report relationships that were preferest? Yes No information below.  Grant? Personal Non-Fin	nitted work.  r you have financial relationships (regardless of amouse line for each entity; add as many lines as you need be sent during the 36 months prior to publication.
Section 3.  Relevant finance  Place a check in the appropriate box of compensation) with entities as declicking the "Add +" box. You should Are there any relevant conflicts of in lif yes, please fill out the appropriate Name of Entity  ehringer Ingelheim	terest? Yes No  ial activities outside the subress in the table to indicate whether escribed in the instructions. Use on a report relationships that were preferest? Yes No information below.  Grant? Personal Non-Fin Supp	nitted work.  r you have financial relationships (regardless of amouse line for each entity; add as many lines as you need be sent during the 36 months prior to publication.
any aspect of the submitted work (inclustatistical analysis, etc.)?  Are there any relevant conflicts of in Relevant finance.  Place a check in the appropriate box of compensation) with entities as declicking the "Add +" box. You should Are there any relevant conflicts of in If yes, please fill out the appropriate.  Name of Entity	terest? Yes No  ial activities outside the subress in the table to indicate whether escribed in the instructions. Use on the report relationships that were preferencest? Yes No information below.  Grant? Personal Non-Fin Suppose S	nitted work.  r you have financial relationships (regardless of amouse line for each entity; add as many lines as you need be sent during the 36 months prior to publication.



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Hoffmann-La Roche, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Travis 1



Section 1.	Identifying Inform	nation	
1. Given Name (Fii William	rst Name)	2. Surname (Last Name) Travis	3. Date 19-July-2017
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Christopher J Ryerson
5. Manuscript Title A Standardized [		r Fibrotic Interstitial Lung	Disease: An International Working Group Perspective
6. Manuscript Ider Blue-201702-040	ntifying Number (if you kr 00PP.R1	now it)	
	ı		
Section 2.	The Work Under Co	onsideration for Public	ation
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	ubmitted work.
of compensation clicking the "Add	) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.
Section 4.	Intellectual Proper	rty Patents & Copyric	ghts
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Travis 2



Section 5.	
Deculon 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Travis has no	thing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Travis 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Udwadia 1



Section 1.	Identifying Inform	nation	
1. Given Name (Fi Zarir	rst Name)	2. Surname (Last Name) Udwadia	3. Date 19-July-2017
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Christopher J Ryerson
5. Manuscript Title A Standardized [		r Fibrotic Interstitial Lung	Disease: An International Working Group Perspective
6. Manuscript Ider Blue-201702-040	ntifying Number (if you kr 00PP.R1	now it)	
	I		
Section 2.	The Work Under C	onsideration for Public	ation
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	ubmitted work.
of compensation clicking the "Add	) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.
Section 4.	Intellectual Prope	rty Patents & Copyric	yhts
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Udwadia 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Udwadia has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Udwadia 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Walsh 1



Section 1. Identifying Inform	nation		
Given Name (First Name) Simon	2. Surname (Last Name) Walsh	3. Date 19-July-2017	
4. Are you the corresponding author?	☐ Yes 🗸 No	Corresponding Author's Name Christopher J Ryerson	
5. Manuscript Title A Standardized Diagnostic Ontology fo	or Fibrotic Interstitial Lung	Disease: An International Working Group Perspectiv	ve
6. Manuscript Identifying Number (if you ki Blue-201702-0400PP.R1	now it)	_	
Section 2. The Work Under C	onsideration for Public	cation	
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, da	n a third party (government, commercial, private foundation at a monitoring board, study design, manuscript preparation	
Section 3. Relevant financial	activities outside the	submitted work.	
of compensation) with entities as descr	ribed in the instructions. Us port relationships that wer est?	nether you have financial relationships (regardless of se one line for each entity; add as many lines as you re <b>present during the 36 months prior to publica</b>	need by
Name of Entity	Grant? Personal Nor	n-Financial Other? Comments	
Boehringer Ingelheim (consultation)			
Sanofi Genzyme (consultation)			
Roche (consultation)			
Google DeenMind			

Walsh 2



Section 4. Intellectual Property Patents & Copyrights				
Do you have any patents, whether planned, pending or issued, broadly relevant to	the work? Yes 🗸 No			
Section 5. Relationships not covered above				
Are there other relationships or activities that readers could perceive to have influe potentially influencing, what you wrote in the submitted work?	nced, or that give the appearance of			
Yes, the following relationships/conditions/circumstances are present (explain below):				
No other relationships/conditions/circumstances that present a potential conflict of interest				
At the time of manuscript acceptance, journals will ask authors to confirm and, if ne On occasion, journals may ask authors to disclose further information about reporte	• •			
Section 6. Disclosure Statement				
Based on the above disclosures, this form will automatically generate a disclosure subelow.	tatement, which will appear in the box			
Dr. Walsh reports personal fees from Boehringer Ingelheim (consultation), personal (consultation), personal fees from Roche (consultation), other from Google DeepMi	·			

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Walsh 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Wells 1



Continue			
Section 1. Identifying Information	ation		
1. Given Name (First Name) Athol	2. Surname (Last Name) Wells	3. Date 19-July-2017	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Christopher J Ryerson	
5. Manuscript Title A Standardized Diagnostic Ontology for	Fibrotic Interstitial Lung I	Disease: An International Working Group Perspective	
6. Manuscript Identifying Number (if you kno Blue-201702-0400PP.R1	ow it)		
Section 2. The Work Under Co	nsideration for Public	ation	
• •	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,	r
Section 3. Relevant financial a	activities outside the s	ubmitted work.	
of compensation) with entities as describ	oed in the instructions. Us ort relationships that wer st?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se <b>present during the 36 months prior to publication</b> .	
Name of Entity	Grant? Personal Nor	n-Financial other? Comments	
Boehringer Ingelheim		Lecturing and consultancy fees	_
Intermune/Roche		Lecturing and consultancy fees	
Bayer		Lecturing and consultancy fees	
Actelion		Lecturing fees	
Chiesi		Lecturing fees	

Wells 2



Section 4. Intellectual Property Patents & Copyrights					
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume					
Section 5. Relationships not covered above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
Yes, the following relationships/conditions/circumstances are present (explain below):					
No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6. Disclosure Statement					
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.					
Dr. Wells reports personal fees from Boehringer Ingelheim, personal fees from Intermune/Roche, personal fees from Bayer, personal fees from Actelion, personal fees from Chiesi, outside the submitted work; .					

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Wells 3